[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100471317":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":46,"centralContacts":50,"locations":56,"responsibleParty":76,"collaborators":45,"id":79,"slug":45,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":45,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":45,"enrollmentInfo":87,"targetDuration":45,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":45,"overallStatus":58,"whyStopped":45,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Ohio State University Comprehensive Cancer Center","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm I (topical minoxidil)","ACTIVE_COMPARATOR","Patients apply minoxidil foam topically to affected areas of the scalp QD for up to 12 months in the absence of disease progression or unacceptable toxicity.",[13,14,15],"Drug: Minoxidil","Other: Quality-of-Life Assessment","Other: Questionnaire Administration",{"label":17,"type":18,"description":19,"interventionNames":20},"Arm II (orally minoxidil)","EXPERIMENTAL","Patients receive minoxidil PO QD for up to 12 months in the absence of disease progression or unacceptable toxicity.",[13,14,15],[22,32,36,42],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Minoxidil","Applied topically",[9],[28,29,30,31],"Alostil","Loniten","Rogaine","U 10858",{"type":23,"name":24,"description":33,"armGroupLabels":34,"otherNames":35},"Given PO",[17],[28,29,30,31],{"type":6,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"Quality-of-Life Assessment","Ancillary studies",[9,17],[41],"Quality of Life Assessment",{"type":6,"name":43,"description":38,"armGroupLabels":44,"otherNames":45},"Questionnaire Administration",[9,17],null,[47],{"name":48,"affiliation":5,"role":49},"Brittany L Dulmage, MD","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":45,"email":55},"The Ohio State University Comprehensive Cancer Center","CONTACT","800-293-5066","OSUCCCClinicaltrials@osumc.edu",[57],{"facility":5,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"RECRUITING","Columbus","Ohio","43210","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-82.99879,39.96118,{"lat":68,"lon":67},[71,75],{"name":72,"role":53,"phone":73,"phoneExt":45,"email":74},"Brittany L. Dulmage, MD","614-565-2554","brittany.dulmage@osumc.edu",{"name":72,"role":49,"phone":45,"phoneExt":45,"email":45},{"type":49,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"Brittany Dulmage","Principal Investigator","100471317",false,"NCT05417308","Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer","A Pilot Trial of Topical vs Oral Minoxidil for Treatment of Endocrine Therapy-Induced Alopecia in Breast Cancer Patients","Inclusion Criteria:\n\n* Women \\>= 18 years of age\n* Established diagnosis of breast cancer stages I-IV\n* On endocrine therapy including tamoxifen or aromatase inhibitors with or without concurrent use of ovarian function suppression\n* Self-reporting hair loss since starting endocrine therapy\n\nExclusion Criteria:\n\n* Pregnant or nursing women\n* Current chemotherapy use or prior chemotherapy use within the last 2 years\n* History of scarring\u002Fcicatricial alopecia or alopecia areata\n* Prior use of oral or topical minoxidil\n* Prior or ongoing use of spironolactone\n* Known sensitivity to minoxidil\n* Untreated hypothyroidism or iron deficiency as determined by thyroid stimulating hormone (TSH) with reflex free T4 and ferritin level \\> 40 to be checked at the time of enrolling if not completed in the 12 months prior","FEMALE","18 Years",{"count":88,"type":89},50,"ESTIMATED","INTERVENTIONAL",[92],"EARLY_PHASE1","This early phase I trial studies the possible benefits and\u002For side effects of topical or oral minoxidil in treating endocrine therapy-induced hair loss (alopecia) in patients with stage I-IV breast cancer. Endocrine therapy-induced alopecia (EIA) is a distressing side effect that leads to reduced quality of life and early cessation of therapy in women undergoing treatment for breast cancer. Patients on endocrine therapy commonly report hair loss or thinning. Minoxidil is a drug that may promote hair growth and reduce hair loss. Oral minoxidil may increase hair density in women with EIA, and work the same as topical minoxidil in treating EIA in patients with breast cancer.",[95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Endocrine Therapy-Induced Alopecia","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8","2026-03-06",{"date":120,"type":121},"2026-03-10","ACTUAL",{"date":123,"type":121},"2023-03-01",{"date":125,"type":89},"2027-12-31",{"name":5,"class":6},1]